FDA approves expanded indication for ADHD treatment from Supernus
The agency has approved an expanded indication for Qelbree extended-release capsules to treat attention deficit hyperactivity disorder in younger patients.
Archives for May 2, 2022
Pistoia Alliance calls for more pharma-patient collaboration in early R&D
A leader from the life-science organization discusses how collaboration could lead to a broad range of benefits for everyone along the drug discovery pipeline